right from the beginning, which is now more than fifty years ago, bruker has been driven by a single idea: to provide the best technological solution for each analytical task. today, worldwide, more than 6,500 employees in over 90 locations on all continents are focusing their efforts on this permanent challenge. bruker systems cover a broad spectrum of applications in all fields of research and development and are used in all industrial production processes for the purpose of ensuring quality and process reliability. bruker continues to build upon its extensive range of products and solutions, expand its broad base of installed systems and maintain a strong reputation amongst its customers. as one of the world's leading analytical instrumentation companies, bruker remains focused on developing state-of-the-art technologies and innovative solutions for today’s ever complex analytical questions. bruker - innovation with integrity. bruker corporation company pages bruker axs: https://www
Company profile
Ticker
BRKR
Exchange
Website
CEO
Frank Laukien
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
BRUKER BIOSCIENCES CORP, BRUKER DALTONICS INC
SEC CIK
Corporate docs
Subsidiaries
Acquifer Imaging GmbH • Acuity Spatial Genomics, Inc. • Agapetus GmbH • Alicona Imaging GmbH • Anasys Instruments Corporation • Biognosys, AG • Biognosys, Inc. • Bruker (Beijing) Scientific Technology Co., Ltd. • Bruker (Malaysia) SDN. BHD. • Bruker Arabia Limited ...
IRS number
43110160
BRKR stock data
Latest filings (excl ownership)
8-K/A
Entry into a Material Definitive Agreement
5 Jun 24
8-K
Bruker Announces Public Offering of Common Stock
31 May 24
424B5
Prospectus supplement for primary offering
30 May 24
8-K
Amendments to Articles of Incorporation or Bylaws
30 May 24
S-3ASR
Automatic shelf registration
29 May 24
SD
Conflict minerals disclosure
23 May 24
ARS
2023 FY
Annual report to shareholders
15 May 24
10-Q
2024 Q1
Quarterly report
10 May 24
8-K
Bruker Reports First Quarter 2024 Financial Results
2 May 24
8-K
Bruker Completes Acquisition of Molecular Diagnostics Innovator ELITech
2 May 24
Transcripts
BRKR
Earnings call transcript
2024 Q1
2 May 24
BRKR
Earnings call transcript
2023 Q4
13 Feb 24
BRKR
Earnings call transcript
2023 Q3
2 Nov 23
BRKR
Earnings call transcript
2023 Q2
3 Aug 23
BRKR
Earnings call transcript
2023 Q2
3 Aug 23
BRKR
Earnings call transcript
2023 Q1
4 May 23
BRKR
Earnings call transcript
2023 Q1
4 May 23
BRKR
Earnings call transcript
2022 Q4
9 Feb 23
BRKR
Earnings call transcript
2022 Q3
3 Nov 22
BRKR
Earnings call transcript
2022 Q2
4 Aug 22
Latest ownership filings
4
FRANK H LAUKIEN
12 Mar 24
4
Hermann Fritz Requardt
6 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
4
Falko Busse
1 Mar 24
144
Notice of proposed sale of securities
28 Feb 24
4
Burkhard Prause
26 Feb 24
144
Notice of proposed sale of securities
22 Feb 24
SC 13G/A
T. Rowe Price Investment Management, Inc.
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
MASSACHUSETTS FINANCIAL SERVICES CO /MA/
9 Feb 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 343.30 mm | 343.30 mm | 343.30 mm | 343.30 mm | 343.30 mm | 343.30 mm |
Cash burn (monthly) | 49.43 mm | 21.51 mm | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 191.13 mm | 83.16 mm | n/a | n/a | n/a | n/a |
Cash remaining | 152.17 mm | 260.14 mm | n/a | n/a | n/a | n/a |
Runway (months of cash) | 3.1 | 12.1 | n/a | n/a | n/a | n/a |
Institutional ownership, Q1 2024
74.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 370 |
Opened positions | 145 |
Closed positions | 37 |
Increased positions | 106 |
Reduced positions | 86 |
13F shares | Current |
---|---|
Total value | 8.59 tn |
Total shares | 108.67 mm |
Total puts | 14.50 k |
Total calls | 210.60 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
T. Rowe Price Investment Management | 13.27 mm | $1.25 bn |
Vanguard | 9.86 mm | $926.29 bn |
BLK Blackrock | 9.71 mm | $912.56 bn |
Pallas Capital Advisors | 9.48 mm | $890.60 bn |
FMR | 9.17 mm | $861.58 bn |
Massachusetts Financial Services | 8.09 mm | $759.87 bn |
RTW Investments | 3.34 mm | $314.14 bn |
STT State Street | 3.25 mm | $305.11 bn |
Alliancebernstein | 2.59 mm | $243.69 bn |
IVZ Invesco | 2.09 mm | $196.35 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
28 Feb 24 | Falko Busse | Common Stock | Sell | Dispose S | No | No | 84.48 | 1,500 | 126.72 k | 32,859 |
28 Feb 24 | Falko Busse | Common Stock | Sell | Dispose S | No | No | 84.97 | 12,770 | 1.09 mm | 34,359 |
28 Feb 24 | Falko Busse | Common Stock | Sell | Dispose S | No | No | 86.06 | 13,852 | 1.19 mm | 47,129 |
28 Feb 24 | Falko Busse | Common Stock | Option exercise | Acquire M | No | No | 41.95 | 4,641 | 194.69 k | 60,981 |
28 Feb 24 | Falko Busse | Common Stock | Option exercise | Acquire M | No | No | 34.02 | 4,384 | 149.14 k | 56,340 |
28 Feb 24 | Falko Busse | Common Stock | Option exercise | Acquire M | No | No | 22.19 | 7,097 | 157.48 k | 51,956 |
28 Feb 24 | Falko Busse | Common Stock | Option exercise | Acquire M | No | No | 19.82 | 12,000 | 237.84 k | 44,859 |
28 Feb 24 | Falko Busse | Stock Option (Right to Purchase) Common Stock | Option exercise | Dispose M | No | No | 41.95 | 4,641 | 194.69 k | 0 |
28 Feb 24 | Falko Busse | Stock Option (Right to Purchase) Common Stock | Option exercise | Dispose M | No | No | 34.02 | 4,384 | 149.14 k | 0 |
28 Feb 24 | Falko Busse | Stock Option (Right to Purchase) Common Stock | Option exercise | Dispose M | No | No | 22.19 | 7,097 | 157.48 k | 0 |
News
Citigroup Maintains Buy on Bruker, Lowers Price Target to $80
10 Jul 24
Goldman Sachs Maintains Sell on Bruker, Lowers Price Target to $60
9 Jul 24
Bruker Launches NeofleX MALDI-TOF System for Spatial Biology Mass Spec Imaging (MSI) Applications, TimsTOF Ultra 2 to Enable New Research Paradigms in Single-Cell and Subcellular Proteomics
3 Jun 24
Why Bruker (BRKR) Shares Are Falling During Thursday's Session
30 May 24
Reported Earlier, Bruker Prices Public Offering Of 6M Shares Of Common Stock
30 May 24
Press releases
Bruker Announces that Injunction Impacting NanoString's CosMx Spatial Molecular Imager Products in Germany Has Been Suspended Effective Immediately
18 Jul 24
Bruker Applied Mass Spectrometry Division Showcases High-Performance Solutions for Research and Analysis in Applied Laboratories
3 Jun 24
Bruker Launches Transformative neofleX™ MALDI-TOF System for Spatial Biology Mass Spec Imaging (MSI) Applications
3 Jun 24
Bruker Launches Ultimate Sensitivity timsTOF Ultra 2 to Enable New Research Paradigms in Single-Cell and Subcellular Proteomics
3 Jun 24
Bruker Corporation to Present at Upcoming Investor Conferences
31 May 24